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Copyright © 200? JCBN Summary Non-steroidal anti-inflammatory drugs (NSAIDs), which are used for the treat-
ment of several inflammatory disorders including rheumatoid arthritis, are well known to
cause gastroduodenal mucosal lesions as an adverse effect. Recently, the serious problem of
NSAID-induced small intestinal damage has become a topic of great interest to gastro-
enterologists, since capsule endoscopy and double-balloon enteroscopy are available for the
detection of small intestinal lesions. Such lesions have been of great concern in clinical settings,
and their treatment and prevention must be devised as soon as possible. Proton pump
inhibitors (PPI), such as lansoprazole and omeprazole, show a potent anti-secretory effect.
PPIs also have a gastroprotective effect, independent of their anti-secretory actions, which is
probably mediated by inhibition of neutrophil functions as well as antioxidant actions.
Administration of lansoprazole reduced the severity of the intestinal lesions in a dose-
dependent manner, but omeprazole had no effect. The amount of heme oxygenase-1 (HO-1)
protein in the intestinal mucosa was significantly increased by lansoprazole, but not by
omeprazole. These results suggest that lansoprazole, but not omeprazole, ameliorates
indomethacin-induced small intestinal ulceration through upregulation of HO-1/carbon
monoxide. Therefore, lansoprazole may be useful for preventing the adverse effects of NSAIDs
not only in the stomach but also in the small intestine.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) in-
cluding indomethacin inhibit prostaglandin (PG) production
at inflamed sites by the inhibition of cyclooxygenase
(COX). NSAIDs are thought to demonstrate their anti-
inflammatory, antipyretic, analgesic, and anti-platelet aggre-
gation effects through this process. NSAIDs have been
used widely in internal medicine and orthopedic surgery.
They have been used to treat febrile diseases, inflammatory
diseases, arthritis, lower back pain, and collagen diseases
and to prevent and treat cerebrovascular diseases and
ischemic heart diseases. PG is an important mediator in the
inflammatory response. It also plays an important role in
maintaining the homeostasis of many tissues and organsK. Higuchi et al.
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including the gastrointestinal tract. When NSAIDs inhibit
COX, they not only exhibit the expected anti-inhibitory
effects but also could cause side effects such as gastro-
intestinal injury [1]. In our aging society, the use of NSAIDs
has continued to increase, and their side effect of gastro-
intestinal mucosal injury has become a clinical problem.
Recently, the serious problem of NSAID-induced small
intestinal damage has become a topic of great interest to
gastroenterologists, since capsule endoscopy and double-
balloon enteroscopy are available for the detection of small
intestinal lesions [2–5]. Such lesions have been of great
concern in clinical settings, and their treatment and pre-
vention must be devised as soon as possible. In this report,
we describe the mechanism and the strategy of NSAID-
induced small bowel injury including prophylactic potential
of lansoprazole.
Mechanisms of NSAID-associated Small Bowel Injury
First, elucidation of mechanism is necessary to devise
measures for small-bowel injury due to NSAIDs. Much
about this mechanism is unknown, but recently more infor-
mation has become evident. A decrease in endogenous PG
has been considered important in the development of
NSAID-induced small-bowel injury [6]. PG is involved in
regulation of gastrointestinal blood flow and various
mucosal functions such as increasing mucus secretion. Thus,
the decrease in PG production is considered to be the main
cause of small bowel injuries due to NSAIDs. In a rat study,
exogenous PG administration was reported to markedly
inhibit small bowel injuries induced by indomethacin, an
NSAID. Besides the reduction of intestinal mucus, NSAIDs
cause microcirculatory disturbances accompanying abnor-
mally increased intestinal motility. Inflammatory cytokines
are induced and neutrophil infiltration occurs. Then intes-
tinal mucosal injuries can occur [7]. The involvement of
NO derived from iNOS is also considered important in the
development of such injuries [8–11].
Bjarnason et al. [12] stated that injury to small bowel
mucosa involves the disruption of intercellular junctions,
resulting in increased mucosal permeability. The disruption
of intercellular junctions occurs because NSAIDs inhibit the
production of mitochondrial ATP in intestinal epithelial
cells. With increased mucosal permeability, mucosal injuries
can be caused by the penetration of bile acid, proteolytic
enzymes, intestinal bacteria, or toxins. Since indomethacin-
induced small-bowel injuries do not develop in rats with
germ-free intestines [13], the involvement of intestinal
bacteria has been reported to be very important in such
injuries. Watanabe et al. studied small bowel injuries
Fig. 1. Mechanisms of NSAID-associated small-bowel injury and the target points of lansoprazole in this mucosal injury. NSAIDs
decrease the mucosal endogenous PG, resulting in the reduction of intestinal mucus, microcirculatory disturbances accompany-
ing abnormally increased intestinal motility, the disruption of intercellular junctions and increased mucosal permeability.
Mucosal injuries can be caused by the penetration of bile acid, proteolytic enzymes, intestinal bacteria, or toxins. At the same
time, inflammatory cytokines are induced and neutrophil infiltration occurs. In addition, a pathway mediated by lipopoly-
saccharide (LPS)/toll-like receptor 4 (TLR4) plays an important role in the development of such injuries. Lansoprazole
ameliorates such small intestinal ulceration through upregulation of HO-1/CO, the inhibition of inflammatory cytokines produc-
tion and neutrophil infiltration.Prevention of NSAID-induced small intestinal injury
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induced by indomethacin in rats. They reported that a
pathway mediated by lipopolysaccharide (LPS)/toll-like
receptor 4 (TLR4) plays an important role in the develop-
ment of such injuries [14]. That is, NSAID-induced small-
intestinal mucosal injuries begin with a PG decrease just as
in NSAID-induced gastric mucosal injuries. Then mucosal
protection declines and microcirculatory disturbances
occur. Unlike gastric mucosal injuries, bacteria in the small
intestine are thought to play an important role instead of
gastric acid (Fig. 1). As mentioned before, NSAIDs inhibit
mucosal PG synthesis by inhibiting COX activity. There are
two types of COX: COX-1 and 2. In particular, COX-1
derived PG has been considered important in maintaining
homeostasis of intestinal mucosa. In recent years, a study
using an animal model has shown that small-intestinal
mucosal injuries occurred only after both COX-1 and 2 were
inhibited [15].
Prophylactic Potential of Lansoprazole to NSAID-
induced Small Bowel Injury
PPI has a strong inhibitory effect on gastric acid secretion.
PPI has been used widely in a clinical setting for Helico-
bacter pylori eradication and for the treatment of gastric
ulcers, duodenal ulcers, reflux esophagitis and NSAID-
induced gastric lesions [16–18]. PPI is also known to have
protective effects on gastrointestinal mucosa without the
inhibition of acid secretion [19–21]. These protective effects
have been reported to occur via anti-inflammatory effects
such as the inhibition of IL-8 production and neutrophil
infiltration and via cell injury repair through MAPK [22–
24]. A study was conducted using a rat model for small-
intestinal mucosal injuries due to ischemia and reperfusion.
Such injuries are said to involve neutrophils and reactive
oxygen species. Lansoprazole inhibited small-intestinal
mucosal injuries due to ischemia and perfusion via inhibi-
tion of neutrophils, lipid peroxidation, and inflammatory
cytokine induction [25]. In addition, PPIs also reduced
NSAID-induced small-intestinal mucosal injuries [26, 27].
We examined the effectiveness of lansoprazole compared
with omeprazole. Male SD rats (200–300 g) were orally
administered 10 mg/kg of indomethacin (IM) and small
bowel injuries were created. Lansoprazole (30–100 mg/kg)
inhibited small bowel injuries in a dose-dependent manner.
Its effectiveness was significant at doses of 60 mg/kg or
more, and the inhibition of 80% or more was observed at a
dose of 100 mg/kg (Fig. 2) [28]. In contrast, omeprazole did
not inhibit such injury at any of the tested doses (30–100
mg/kg). Pretreatment with lansoprazole inhibited the MPO
activity and iNOS mRNA expression which were increased
by indomethacin. The different effectiveness of lansoprazole
compared with omeprazole cannot be fully explained by
previously reported mechanisms [29–32].
An Anti-inflammatory Effect of Lansoprazole via
Upregulation of HO-1/CO
The development of NSAID-induced ulcers cannot be
explained by PG reduction alone. It has been recently
reported that NSAID-induced cell death of gastric mucosa is
necessary in the mechanism of NSAID-associated gastric
mucosal injury [33, 34]. NSAIDs induce heme oxygenase-1
(HO-1) and this induction inhibits NSAID-dependent cell
death. HO-1 is also called heat shock protein 32 (HSP 32)
and is the rate limiting enzyme of heme metabolism. It
degrades free heme which has high cytotoxicity. This
degradation produces highly cytoprotective carbon mon-
oxide (CO) and biliverdin, resulting in a cytoprotective
effect [35–37] (Fig. 3). In recent years, CO has been
reported to demonstrate a strong anti-inflammatory effect.
CO has shown this effect by p38 MAP kinase activation,
inhibiting the production of inflammatory cytokines, such as
TNF-α and IL-1β, and inducing the production of anti-
inflammatory cytokine, IL-10 [38–40].
Mizushima et al. [41]. reported the following three points.
NSAID-induced cell death of gastric mucosa is essential in
the development of NSAID-induced gastric ulcers. NSAIDs
induce HO-1 in vitro and in vivo via Nrf2 activation. This
induction inhibits NSAID-dependent cell death of gastric
mucosa, resulting in the inhibition of the development of
NSAID-induced ulcers. HO-1 expression is induced mainly
Fig. 2. Effects of lansoprazole on indomethacin-induced intesti-
nal lesions in rats. Animals were given indomethacin
(10 mg/kg, p.o.) and sacrificed 24 h later. Lansoprazole
(30, 60, and 100 mg/kg) were given p.o. 30 min before
the administration of indomethacin. Data are presented
as the mean ± SE from 6 rats. *Statistically significant
difference from control (vehicle alone) at p<0.05. Re-
printed with permission [28].K. Higuchi et al.
J. Clin. Biochem. Nutr.
128
in macrophage cell lines and vascular endothelial cells under
various stresses such as exposure to heavy metals and active
oxygen species. When there is an increase in heme degrada-
tion by HO-1, cytoprotection occurs by the biochemical
actions of various resulting degradation products [42, 43].
In addition, lansoprazole has been reported to induce HO-1
[44], and thus, HO-1 is thought to be involved in the inhibi-
tion of NSAID-associated small bowel injuries. We intra-
venously administered an HO-1 inhibitor SnPP (30 mg/kg)
in rats [45]. It was administered 10 min before indomethacin
administration. Pretreatment with SnPP aggravated small
bowel injuries induced by indomethacin. On the contrary,
pretreatment with both lansoprazole (100 mg/kg) and SnPP
clearly aggravated mucosal injuries. HO-1 expression was
examined using an ELISA kit (Stressgen, Rat HO-1 ELISA
Kit) and immunoreaction. HO-1 is usually not expressed in
normal rats. It was expressed in the mucosal epithelium 6 h
after indomethacin (10 mg/kg) and lansoprazole (100 mg/kg)
administrations. These results suggested that HO-1 is
involved in the mechanism for inhibiting indomethacin-
induced small bowel injuries using lansoprazole. CORM-2
(10 mg/kg) was administered intraperitoneally 30 min before
and 6 h after indomethacin administration. Indomethacin-
induced small bowel injuries were markedly inhibited. iNOS
mRNA expression was also inhibited 6 h after indomethacin
administration. In a recent study, CO released by CORM-2
was reported to inhibit NO and TNF-α production in mice
[46, 47]. There has been a report indicating that CO has an
anti-inflammatory effect in DLD-1, a human colorectal
cancer cell line [48]. Another report indicated that CO has an
anti-inflammatory effect by inhibiting NFκB activity [49,
50]. Still another report showed that indomethacin activates
NFκB in the small intestine, and the immunosuppressant
tacrolimus inhibits NFκB activity [51]. Thus, lansoprazole
inhibits NFκB activity via upregulation of HO-1/CO,
suggesting the possible involvement of iNOS inhibition.
Conclusion
We have described the mechanism of and potential
measures for NSAID-induced small-bowel injuries. The
whole gastrointestinal tract must be managed in this era of
increasing NSAID use. In considering this point, we can say
that lansoprazole is a useful drug that can potentially protect
the stomach and small intestine. We hope to examine these
issues in future clinical studies.
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